ArticleResearch square2026
Armed Oncolytic Myxoma Virus Induces Systemic Antitumor Immunity Against Solid Tumors in Immunocompetent Mice.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Oncolytic viruses expressing immunostimulatory transgenes can enhance immune cells recruitment into the tumor bed and activate potent antitumor immune responses. In this study, we evaluated oncolytic activity of recombinant myxoma virus (MYXV) variants expressing murine LIGHT, murine mIL-15, or IL-15Rα-IL-15 fusion protein. All recombinant MYXVs demonstrated similar replication kinetics and cytotoxic activity in cancer cell lines. Their therapeutic efficacy was further assessed in a bilateral tumor model in immunocompetent mice, where only one tumor received intratumoral treatment. We observed significant tumor regression in both injected and uninjected contralateral tumors following treatment with MYXV expressing IL-15Rα-IL-15 (vMyx-IL15Rα) or mLIGHT (vMyx-mLIGHT), indicating the activation of systemic antitumor immunity. Additionally, vMyx-IL15Rα- treated mice survived significantly longer than any of the other treatments. Analysis of tumor-infiltrating lymphocytes revealed that vMyx-IL15Rα increased effector memory CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.